FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377013627> ?p ?o ?g. }

• W4377013627 abstract "Abstract Background. The C-terminal-binding protein 1/brefeldin A ADP-ribosylation substrate (CtBP1/BARS) acts both as an oncogenic transcriptional co-repressor and as a fission inducing protein required for membrane trafficking and Golgi complex partitioning during mitosis, hence for mitotic entry. CtBP1/BARS overexpression, in multiple cancers, has pro-tumorigenic functions regulating gene networks associated with “cancer hallmarks” and malignant behavior including: increased cell survival, proliferation, migration/invasion, epithelial-mesenchymal transition (EMT). Structurally, CtBP1/BARS belongs to the hydroxyacid-dehydrogenase family and possesses a NAD(H)-binding Rossmann fold, which, depending on ligands bound, controls the oligomerization of CtBP1/BARS and, in turn, its cellular functions. Here, we proposed to target the CtBP1/BARS Rossmann fold with small molecules as selective inhibitors of mitotic entry and pro-tumoral transcriptional activities. Methods. Structured-based screening of drug databases at different development stages was applied to discover novel ligands targeting the Rossmann fold. Among these identified ligands, N-(3,4-dichlorophenyl)-4-{[(4-nitrophenyl)carbamoyl]amino}benzenesulfonamide , called Comp.11, was selected for further analysis. Fluorescence spectroscopy, isothermal calorimetry, computational modelling and site-directed mutagenesis were employed to define the binding of Comp.11 to the Rossmann fold. Effects of Comp.11 on the oligomerization state, protein partners binding and pro-tumoral activities were evaluated by size-exclusion chromatography, pull-down, membrane transport and mitotic entry assays, Flow cytometry, quantitative real-time PCR, motility/invasion, and colony assays in A375MM and B16F10 melanoma cell lines. Effects of Comp.11 on tumor growth in vivo were analyzed in mouse tumor model. Results. We identify Comp.11 as a new, potent and selective inhibitor of CtBP1/BARS (but not CtBP2). Comp.11 directly binds to the CtBP1/BARS Rossmann fold affecting the oligomerization state of the protein (unlike other known CtBPs inhibitors), which, in turn, hinders interactions with relevant partners, resulting in the inhibition of both CtBP1/BARS cellular functions: i) membrane fission, with block of mitotic entry and cellular secretion; and ii) transcriptional pro-tumoral effects with significantly hampered proliferation, EMT, migration/invasion, and colony-forming capabilities. The combination of these effects impairs melanoma tumor growth in mouse models. Conclusions. This study identifies a potent and selective inhibitor of CtBP1/BARS active in cellular and melanoma animal models revealing new opportunities to study the role of CtBP1/BARS in tumor biology and to develop novel melanoma treatments." @default.
• W4377013627 created "2023-05-19" @default.
• W4377013627 creator A5005150917 @default.
• W4377013627 creator A5014751156 @default.
• W4377013627 creator A5016647549 @default.
• W4377013627 creator A5022723432 @default.
• W4377013627 creator A5023219638 @default.
• W4377013627 creator A5032283822 @default.
• W4377013627 creator A5035710316 @default.
• W4377013627 creator A5041252015 @default.
• W4377013627 creator A5041812067 @default.
• W4377013627 creator A5046167549 @default.
• W4377013627 creator A5047098934 @default.
• W4377013627 creator A5064247598 @default.
• W4377013627 creator A5064352497 @default.
• W4377013627 creator A5065972464 @default.
• W4377013627 creator A5066063513 @default.
• W4377013627 creator A5067725142 @default.
• W4377013627 creator A5071399703 @default.
• W4377013627 creator A5076045755 @default.
• W4377013627 creator A5077715520 @default.
• W4377013627 creator A5079288545 @default.
• W4377013627 creator A5086057803 @default.
• W4377013627 creator A5090544235 @default.
• W4377013627 date "2023-05-18" @default.
• W4377013627 modified "2023-09-29" @default.
• W4377013627 title "Identification and characterization of a new potent inhibitor targeting CtBP1/BARS in melanoma cells" @default.
• W4377013627 cites W1040915469 @default.
• W4377013627 cites W1207770767 @default.
• W4377013627 cites W1488084349 @default.
• W4377013627 cites W1603850660 @default.
• W4377013627 cites W1754492371 @default.
• W4377013627 cites W1968003842 @default.
• W4377013627 cites W1969389753 @default.
• W4377013627 cites W1971512164 @default.
• W4377013627 cites W1973469475 @default.
• W4377013627 cites W1978916168 @default.
• W4377013627 cites W1979406565 @default.
• W4377013627 cites W1987951406 @default.
• W4377013627 cites W1988329333 @default.
• W4377013627 cites W1988378772 @default.
• W4377013627 cites W1996579961 @default.
• W4377013627 cites W1996751621 @default.
• W4377013627 cites W2001378844 @default.
• W4377013627 cites W2001888120 @default.
• W4377013627 cites W2002760530 @default.
• W4377013627 cites W2002761920 @default.
• W4377013627 cites W2003223749 @default.
• W4377013627 cites W2004951157 @default.
• W4377013627 cites W2007066447 @default.
• W4377013627 cites W2007134398 @default.
• W4377013627 cites W2007617487 @default.
• W4377013627 cites W2009459756 @default.
• W4377013627 cites W2009742641 @default.
• W4377013627 cites W2009916814 @default.
• W4377013627 cites W2012572985 @default.
• W4377013627 cites W2013535625 @default.
• W4377013627 cites W2022182252 @default.
• W4377013627 cites W2024301699 @default.
• W4377013627 cites W2026604603 @default.
• W4377013627 cites W2042292074 @default.
• W4377013627 cites W2042521915 @default.
• W4377013627 cites W2046474853 @default.
• W4377013627 cites W2047109055 @default.
• W4377013627 cites W2048122656 @default.
• W4377013627 cites W2055501079 @default.
• W4377013627 cites W2067991344 @default.
• W4377013627 cites W2069506255 @default.
• W4377013627 cites W2074395695 @default.
• W4377013627 cites W2076616447 @default.
• W4377013627 cites W2078339225 @default.
• W4377013627 cites W2079300137 @default.
• W4377013627 cites W2080528403 @default.
• W4377013627 cites W2081527131 @default.
• W4377013627 cites W2081976888 @default.
• W4377013627 cites W2082601129 @default.
• W4377013627 cites W2090378429 @default.
• W4377013627 cites W2092950132 @default.
• W4377013627 cites W2104076764 @default.
• W4377013627 cites W2108764571 @default.
• W4377013627 cites W2110256992 @default.
• W4377013627 cites W2111365962 @default.
• W4377013627 cites W2119752391 @default.
• W4377013627 cites W2124896191 @default.
• W4377013627 cites W2127294067 @default.
• W4377013627 cites W2130217598 @default.
• W4377013627 cites W2130590579 @default.
• W4377013627 cites W2131411847 @default.
• W4377013627 cites W2132819585 @default.
• W4377013627 cites W2136272810 @default.
• W4377013627 cites W2138414111 @default.
• W4377013627 cites W2141248073 @default.
• W4377013627 cites W2149290739 @default.
• W4377013627 cites W2152025793 @default.
• W4377013627 cites W2153481815 @default.
• W4377013627 cites W2157140423 @default.
• W4377013627 cites W2160090208 @default.
• W4377013627 cites W2167835377 @default.
• W4377013627 cites W2170183018 @default.
• W4377013627 cites W2235245255 @default.

• next